Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt (Details)

v2.4.0.6
Long-Term Debt (Details)
3 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2013
USD ($)
Mar. 31, 2012
USD ($)
Mar. 31, 2013
Novartis Note [Member]
USD ($)
Mar. 31, 2012
Novartis Note [Member]
USD ($)
Dec. 31, 2012
Novartis Note [Member]
USD ($)
Mar. 31, 2013
Servier Loan [Member]
USD ($)
Mar. 31, 2012
Servier Loan [Member]
USD ($)
Jul. 15, 2013
Servier Loan [Member]
Jan. 15, 2013
Servier Loan [Member]
Jul. 15, 2012
Servier Loan [Member]
Jan. 15, 2012
Servier Loan [Member]
Dec. 31, 2012
Servier Loan [Member]
USD ($)
Dec. 31, 2011
Servier Loan [Member]
USD ($)
Mar. 31, 2013
Servier Loan [Member]
EUR (€)
Sep. 30, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
Mar. 31, 2013
General Electric Capital Corporation Term Loan [Member]
USD ($)
Mar. 31, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
Dec. 31, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
Sep. 27, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
Dec. 31, 2011
General Electric Capital Corporation Term Loan [Member]
USD ($)
Mar. 31, 2013
Other Financings [Member]
USD ($)
Mar. 31, 2012
Other Financings [Member]
USD ($)
Debt Instrument [Line Items]                                            
Maturity date     Jun. 30, 2015                         Jun. 15, 2015            
Research and development expenses funded through loan facility, maximum (in hundredths)     75.00%                                      
Maximum borrowing capacity under loan agreement     $ 50,000,000                     € 15,000,000                
Variable rate basis     six-month LIBOR     Euro Inter-Bank Offered Rate ("EURIBOR")                                
Basis spread on variable rate (in hundredths)     2.00%                                      
Interest rate at period end (in hundredths) 2.51%                                          
Outstanding principal balance     14,400,000   14,400,000 19,200,000           19,800,000       12,500,000   12,500,000 3,100,000 10,000,000    
Periodic Payment, Principal                             347,222              
Proceeds from loan                         19,500,000   4,600,000              
Increase (Decrease) in term loan obligation                             12,500,000              
Initial interest rate during period (in hundredths)                       3.22%                    
Interest rate during period (in hundredths)               2.33% 2.80% 3.54% 3.83%                      
Unamortized discount on debt           8,900,000                                
Unrealized foreign exchange gain (loss) 440,000 (376,000)       600,000 (600,000)                              
Unrealized foreign exchange gains related to re-measurement of loan discount           200,000 200,000                              
Euro to US Dollar exchange rates                               1.2816 1.3215          
Amortization period for loan discount           5 years                                
Amortization of debt discount           400,000 300,000                              
Carrying value of the loan           14,200,000           14,200,000                    
Recognition of deferred revenue           400,000 300,000                              
Debt issuance costs                             200,000 1,300,000            
Final payment fee                               500,000     875,000      
Fixed interest rate accrued (in hundredths)                               11.71%     10.90%      
Number of monthly installments                             27 42            
Prepayment premium year one (in hundredths)                               3.00%            
Prepayment premium year two (in hundredths)                               2.00%            
Prepayment premium year thereafter (in hundredths)                               1.00%            
Aggregate number of unregistered shares of common stock called by warrants (in shares)                               263,158     39,346      
Warrants exercise price (in dollars per share)                               $ 1.14     $ 3.54      
Immediate Term for warrants exercisable (in years)                             5 years 5 years            
Fair value of warrant liability 33,000                             200,000     100,000      
Interest expense and amortization of debt issuance costs [Abstract]                                            
Interest expense $ 1,172,000 $ 1,042,000 $ 91,000 $ 99,000   $ 525,000 $ 516,000                 $ 545,000 $ 417,000       $ 11,000 $ 10,000